Summit Therapeutics monotherapy ivonescimab results from their Phase 3 trial to treat locally advanced or metastatic non-small cell lung cancer was well received by the market. Over 3x their stock price and added over US$3bn to their market cap. Allowed them to raise $200M to expands their license territories for Ivonescimab. Only Phase 1 for Imugene's Oasis Trial, can't wait to see the results and market reaction if the trials are successful even at this early stage.
Why IMU is a multi multi bagger, page-24129
-
- There are more pages in this discussion • 2,874 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.9¢ | $900.1K | 18.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 15456501 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 1713619 | 8 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |